1. Home
  2. MBWM vs VOR Comparison

MBWM vs VOR Comparison

Compare MBWM & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBWM

Mercantile Bank Corporation

SELL

Current Price

$60.21

Market Cap

1.1B

Sector

Finance

ML Signal

SELL

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

SELL

Current Price

$19.11

Market Cap

1.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MBWM
VOR
Founded
1997
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
MBWM
VOR
Price
$60.21
$19.11
Analyst Decision
Hold
Strong Buy
Analyst Count
6
10
Target Price
★ $64.17
$39.00
AVG Volume (30 Days)
99.0K
★ 646.8K
Earning Date
10-20-2026
10-30-2026
Dividend Yield
★ 2.64%
N/A
EPS Growth
★ 10.95
N/A
EPS
★ 4.21
N/A
Revenue
N/A
N/A
Revenue This Year
$16.34
N/A
Revenue Next Year
$7.39
N/A
P/E Ratio
$14.37
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.40
$6.50
52 Week High
$63.41
$26.00

Technical Indicators

Market Signals
Indicator
MBWM
VOR
Relative Strength Index (RSI) 49.24 47.33
Support Level $56.97 $17.62
Resistance Level $62.64 $20.11
Average True Range (ATR) 1.40 1.23
MACD -0.03 0.01
Stochastic Oscillator 16.29 28.77

Price Performance

Historical Comparison
MBWM
VOR

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: